Category Added in a WPeMatico Campaign
Bristol Myers Squibb Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer’s Disease
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ADEPT--BMS Presents First Clinical Data from Two Phase 3 Studies in more...